PT-141 (Bremelanotide) vs Semax
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
PT-141 (Bremelanotide)Cognitive Enhancement
Semax- Summary
- PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
- Semax is a synthetic heptapeptide derived from ACTH developed in Russia. It is a potent nootropic that enhances memory, focus, and provides neuroprotection. Approved in Russia for cognitive disorders, stroke recovery, and traumatic brain injury.
- Half-Life
- 2–3 hours
- Minutes (but effects persist for hours via BDNF induction)
- Admin Route
- SubQ
- Intranasal, SubQ
- Research
- —
- —
- Typical Dose
- 0.5–1.75 mg
- 0.25–1 mg (250–1000 mcg)
- Frequency
- As needed (not daily)
- 1–2 times daily
- Key Benefits
- Enhances sexual desire and libido in both men and women
- Improves arousal through central nervous system activation
- Effective for psychological erectile dysfunction
- Works for female sexual arousal disorder
- May improve sexual satisfaction and intensity
- Fast-acting — effects within 45–60 minutes
- FDA-approved for HSDD in premenopausal women
- Enhances memory and learning
- Improves focus and concentration
- Increases mental energy and motivation
- Provides neuroprotection via BDNF and NGF upregulation
- Reduces cognitive decline
- May alleviate ADHD symptoms
- Supports recovery from brain injury and stroke
- Fast-acting — effects within 30–60 minutes
- Approved in Russia for cognitive disorders and stroke recovery
- Side Effects
- Nausea (most common — 40% of users in clinical trials)
- Facial flushing and warmth
- Transient blood pressure changes (typically increase then normalize)
- Headache
- +2 more
- Headache (rare, often from higher doses)
- Anxiety or overstimulation at high doses
- Sleep disruption if dosed too late
- Irritability (uncommon)
- Stacks With
- —
- —